BioCentury | Jun 26, 2019
Distillery Therapeutics

RTN4 and S1PR2 identified as targets for stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke A team led by NovaGo Therapeutics co-founder Martin Schwab showed inhibition of RTN4 or its receptor S1PR2 could help treat stroke. In mice, levels of RTN4 and S1PR2 were elevated...
BioCentury | May 15, 2018
Distillery Therapeutics

Neurology

...and mouse studies suggest antagonizing OPRL1 alone or in combination with inhibiting its downstream effector RTN4R...
...compared with vehicle. In another mouse model of SCI, the OPRL1 antagonist plus knockout of RTN4R...
...treat depression and neurobehavioral disorders. TARGET/MARKER/PATHWAY: Opioid related nociceptin receptor 1 (OPRL1; NOPR); reticulon 4 receptor (RTN4R; NGR...
BioCentury | Nov 30, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: November 2017

New Therapeutic Targets and Biomarkers: November 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during November 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Nov 27, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Dengue fever; West Nile virus; Zika virus Cell culture studies suggest inhibiting the host factor RTN3 could help treat dengue fever, West Nile and Zika infections. In HeLa cells infected with dengue, West Nile...
BioCentury | Jan 11, 2017
Distillery Therapeutics

Neurology

...INDICATION: Stroke Mouse studies suggest inhibiting signaling between RTN4R , RTN4RL2 and their ligands could help...
...in normal mice. In a young adult mouse model of white matter stroke, a chimeric RTN4R-RTN4RL2-Fc...
...against RTN4, in Phase I testing for spinal cord injury (SCI). TARGET/MARKER/PATHWAY: Reticulon 4 receptor (RTN4R; NGR); reticulon 4 receptor-like...
BioCentury | Jan 7, 2016
Strategy

Imaging

...imaging showed reticulon 4 receptor ( RTN4R ; NGR ) knockout increased axon regeneration compared with normal RTN4R...
BioCentury | Jul 17, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage; stroke Reticulon 4 (RTN4; NOGO-A; NOGO; NOGO-B) Rat studies suggest treatment with NOGO-A inhibitors followed by physical therapy could help improve motor recovery...
BioCentury | Jul 14, 2014
Finance

2Q Stock Wrap-Up: Large and in charge

...Trobalt had no additional benefit, and GSK requested a new benefit assessment MolMed S.p.A. (Milan:MLM) NGR-hTNF...
BioCentury | May 12, 2014
Clinical News

NGR-hTNF: Phase III data

...disease progressed after a pemetrexed-based chemotherapy showed that second-line treatment with once-weekly 0.8 µg/m 2 NGR-hTNF...
...vinorelbine). In a pre-specified subgroup of patients who progressed during or shortly after first-line chemotherapy, NGR-hTNF...
...months after first-line chemotherapy, which was the median treatment-free interval for the overall study population. NGR-hTNF...
BioCentury | May 12, 2014
Finance

Highlights of weekly biotech stock moves

...MolMed S.p.A. (Milan:MLM) was off €0.06 to €0.68 last week after saying second-line treatment with NGR-hTNF...
...survival vs. placebo plus BIC in a Phase III trial to treat malignant pleural mesothelioma. NGR-hTNF...
Items per page:
1 - 10 of 74